IP Library › Granted Patent US 7,691,373
Granted Patent B2
US 7,691,373 · App. 11/620,440 · Granted Apr 6, 2010

Isolated mammalian membrane proteins; related agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,691,373
App. No.
11/620,440
Granted
Apr 6, 2010
Kind
B2
Abstract

Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Claims (23)

1. An isolated antibody that specifically binds the polypeptide set forth in SEQ ID NO: 2, or an antigen binding fragment thereof.

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody or antigen binding fragment of claim 1 , wherein said antibody or antigen binding fragment is bound to a solid support.

4. The antibody or antigen binding fragment of claim 1 , wherein said antibody or antigen binding fragment is labeled.

5. The antigen binding fragment of claim 1 , wherein the antigen binding fragment is from a monoclonal antibody.

6. A composition comprising the antibody or antigen binding fragment of claim 1 and one or more pharmaceutically acceptable carriers.

7. The composition of claim 6 , wherein said composition is suitable for parenteral administration.

8. The composition of claim 6 , wherein said composition is suitable for intravenous administration.

9. The composition of claim 6 , wherein said composition is suitable for subcutaneous administration.

10. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment binds the polypeptide set forth in SEQ ID NO:2 with a K D of at least 300 μM.

11. The antibody or antigen binding fragment of claim 10 , wherein the antibody or antigen binding fragment binds the polypeptide set forth in SEQ ID NO:2 with a K D of at least 10 μM.

12. An isolated antibody that specifically binds the polypeptide set forth in SEQ ID NO: 4, or an antigen binding fragment thereof.

13. The antigen binding fragment of claim 12 , wherein the antigen binding fragment is from a monoclonal antibody.

14. The antibody of claim 12 , wherein the antibody is a monoclonal antibody.

15. The antibody or antigen binding fragment of claim 12 , wherein said antibody or antigen binding fragment is bound to a solid support.

16. The antibody or antigen binding fragment of claim 12 , wherein said antibody or antigen binding fragment is labeled.

17. A composition comprising the antibody or antigen binding fragment of claim 12 and one or more pharmaceutically acceptable carriers.

18. The composition of claim 17 , wherein said composition is suitable for parenteral administration.

19. The composition of claim 17 , wherein said composition is suitable for intravenous administration.

20. The composition of claim 17 , wherein said composition is suitable for subcutaneous administration.

21. The antibody or fragment of claim 12 , wherein said antibody or antigen binding fragment binds to residues 118-144 of SEQ ID NO:4.

22. The antibody or antigen binding fragment of claim 12 , wherein the antibody or antigen binding fragment binds the polypeptide set forth in SEQ ID NO:4 with a K D of at least 300 μM.

23. The antibody or antigen binding fragment of claim 22 , wherein the antibody or antigen binding fragment binds the polypeptide set forth in SEQ ID NO:4 with a K D of at least 10 μM.